Rhumbline Advisers Increases Stock Holdings in Petmed Express Inc (NASDAQ:PETS)

Rhumbline Advisers boosted its position in Petmed Express Inc (NASDAQ:PETS) by 43.8% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 149,065 shares of the company’s stock after purchasing an additional 45,387 shares during the period. Rhumbline Advisers owned about 0.74% of Petmed Express worth $2,686,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. State of New Jersey Common Pension Fund D bought a new position in shares of Petmed Express in the third quarter worth about $2,746,000. Ridgewood Investments LLC raised its stake in shares of Petmed Express by 8.9% in the third quarter. Ridgewood Investments LLC now owns 36,044 shares of the company’s stock worth $650,000 after buying an additional 2,938 shares during the period. 6 Meridian bought a new position in shares of Petmed Express in the third quarter worth about $586,000. Fox Run Management L.L.C. bought a new position in shares of Petmed Express in the third quarter worth about $241,000. Finally, Rothschild Investment Corp IL raised its stake in shares of Petmed Express by 5.7% in the third quarter. Rothschild Investment Corp IL now owns 192,661 shares of the company’s stock worth $3,472,000 after buying an additional 10,333 shares during the period. 97.46% of the stock is currently owned by hedge funds and other institutional investors.

PETS traded up $0.10 on Tuesday, hitting $23.20. 9,924 shares of the company’s stock traded hands, compared to its average volume of 1,274,191. The company’s 50 day simple moving average is $20.95 and its 200-day simple moving average is $18.23. The firm has a market cap of $466.85 million, a price-to-earnings ratio of 17.94 and a beta of 0.63. Petmed Express Inc has a one year low of $15.00 and a one year high of $28.38.

Petmed Express (NASDAQ:PETS) last issued its earnings results on Monday, October 21st. The company reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.07. The company had revenue of $69.94 million for the quarter, compared to the consensus estimate of $69.65 million. Petmed Express had a return on equity of 20.45% and a net margin of 9.62%. The firm’s quarterly revenue was down 2.0% on a year-over-year basis. During the same quarter last year, the company earned $0.52 EPS.

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 15th. Investors of record on Monday, November 4th will be paid a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 4.66%. The ex-dividend date of this dividend is Friday, November 1st.

In other Petmed Express news, Director Gian Fulgoni sold 12,000 shares of Petmed Express stock in a transaction that occurred on Wednesday, October 23rd. The stock was sold at an average price of $26.45, for a total value of $317,400.00. Following the sale, the director now owns 58,900 shares of the company’s stock, valued at approximately $1,557,905. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 4.00% of the company’s stock.

Several research firms have recently commented on PETS. TheStreet raised Petmed Express from a “c” rating to a “b-” rating in a research note on Tuesday, October 22nd. BidaskClub raised Petmed Express from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Craig Hallum raised their price objective on Petmed Express from $15.00 to $20.00 and gave the stock a “hold” rating in a research note on Thursday, October 17th. Finally, ValuEngine raised Petmed Express from a “sell” rating to a “hold” rating in a research note on Wednesday, October 2nd.

Petmed Express Company Profile

PetMed Express, Inc and its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. It markets prescription and non-prescription pet medications, and other health products for dogs and cats directly to the consumers. The company offers non-prescription medications and supplies, including flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, such as heartworm preventative, flea and tick preventative, arthritis, thyroid, diabetes, pain, heart/blood pressure, and other specialty medications, as well as generic substitutes.

Read More: Marijuana Stocks Future Looks Bright

Want to see what other hedge funds are holding PETS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Petmed Express Inc (NASDAQ:PETS).

Institutional Ownership by Quarter for Petmed Express (NASDAQ:PETS)

Receive News & Ratings for Petmed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petmed Express and related companies with MarketBeat.com's FREE daily email newsletter.